Consumer Business Reliable And Right At Home At GlaxoSmithKline
This article was originally published in The Pink Sheet
Executive Summary
CEO Walmsley's familiarity with Glaxo's consumer health business was clear in her response to analysts' questions about the firm's future as a three-unit operation. The business marketing brands including Flonase and Excedrin is a more reliable revenue driver than the pharma business, she said.
You may also be interested in...
From Witty To Walmsley – The Priorities For GSK's New CEO
It's Emma Walmsley's first week at the helm of GlaxoSmithKline. What can we expect in terms of her priorities?
Glaxo’s Parodontax Brings Bleeding Gums Claim To US Toothpaste Battle
Parodontax contains the same OTC oral care monograph ingredient, stannous fluoride, as numerous toothpastes labeled for use on sensitive teeth, but those products don’t include the indication of helping stop bleeding gums.
GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition
GlaxoSmithKline Flonase Sensimist Allergy Relief could help fend off private label competition in the intranasal corticosteroid category, the firm says. Despite a 19% drop in sales of the original Flonase OTC in the fourth quarter, US consumer health care sales grew 5% to $2.2bn on a reported basis in 2016.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: